단백질체학 시장 규모 : 기기 기술별, 시약별, 소프트웨어 및 서비스별, 용도별, 최종사용자별, 지역별, 범위 및 예측

Proteomics Market Size And Forecast

Proteomics Market size was valued at USD 32.65 Billion in 2023 and is projected to reach USD 97.23 Billion by 2031, growing at a CAGR of 14.62% from 2024 to 2031. Proteomics is the study of all proteins found in a biological sample, such as cells, tissues, or organisms. It entails identifying, characterizing, and quantifying proteins, as well as investigating their interactions, changes, and activities within biological systems. Proteomics includes a diverse set of techniques and approaches, such as mass spectrometry, gel electrophoresis, protein microarrays, and bioinformatics tools. Proteomics has a wide range of applications, including biomedical research, drug development, personalized treatment, and agriculture.

Furthermore, proteomics promotes agricultural research by increasing crop output, quality, and tolerance to environmental challenges.

Global Proteomics Market Dynamics

The key market dynamics that are shaping the Proteomics Market include:

Key Market Drivers

Increasing Prevalence of Chronic Diseases:

The growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease is propelling the demand for proteome research. This research is critical in understanding disease pathology, which will lead to the development of targeted medicines and personalized medicine, and propel market demand.

Growing Investment in Research and Development:

The government and corporate sectors are increasing their allocation of cash for proteome research. This financing supports proteome research, which will lead to substantial advances in disease diagnostics, drug discovery, and treatment monitoring and fosters the market to move forward.

Technological Advancements:

Mass spectrometry and bioinformatics advances have made proteomics research substantially more effective. These developments make protein analysis more precise, sensitive, and faster, allowing for a better knowledge of cellular processes and disease mechanisms, and driving market expansion.

Expansion of Pharmaceutical and Biotechnology Industries:

The pharmaceutical and biotechnology industries are quickly increasing, with a significant emphasis on new drug discovery and precision medicine. Proteomics is crucial in these industries because it identifies novel drug targets and biomarkers, streamlines the drug development process and improves drug efficacy and safety.

Key Challenges:

High Cost of Proteomics Research:

Advanced proteomics technologies, such as mass spectrometry and high-throughput sequencing, need a large investment in equipment and maintenance. The hefty prices limit access for smaller research institutes and prevent widespread adoption.

Complexity of the Proteome:

The human proteome is extremely complicated, with a large number of proteins that undergo post-translational changes. This complexity makes it difficult to precisely identify and quantify proteins, necessitating expensive analytical techniques and computational tools, and restricting market expansion.

Limited Biomarker Validation:

Despite the discovery of multiple possible biomarkers through proteomic research, the validation process for clinical usage is lengthy and difficult. Thus, severe validation requirements, combined with the necessity for large-scale investigations to prove clinical relevance, hinder the translation of proteomic discoveries into diagnostics and therapies.

Key Trends:

Advancements in Mass Spectrometry Technology:

Mass spectrometry's continuous advances, including improved sensitivity, resolution, and throughput, allow for more thorough proteome investigations. This trend enables a more in-depth investigation of the proteome, including post-translational changes and protein-protein interactions.

Growth in Personalized Medicine:

Proteomics is becoming more widely used in personalized medicine, with an emphasis on discovering biomarkers for illness diagnosis, prognosis, and medication selection. This trend is accelerating the development of targeted medicines and personalized healthcare strategies based on individual proteome profiles.

Collaborative Research and Multi-Omics Approaches:

There is an increasing emphasis on collaborative research and the use of multi-omics techniques that include proteomics, genomics, transcriptomics, and metabolomics. This holistic view of biological systems allows for a more complete knowledge of disease mechanisms and the identification of new treatment targets.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Proteomics Market Regional Analysis

Here is a more detailed regional analysis of the Proteomics Market:

North America:

According to Verified Market Research, North America is estimated to dominate the market over the forecast period. North America, particularly the United States, has a sophisticated research infrastructure, with world-class research institutes and laboratories. This allows for cutting-edge proteomics research and technical innovation, resulting in the region's dominance in the Proteomics Market.

The region has received significant government and private sector funding in biotechnology and pharmaceutical research, including proteomics. This financing supports a diverse spectrum of proteomics initiatives, from basic research to therapeutic applications, hence promoting market growth.

Chronic diseases such as cancer, cardiovascular disease, and diabetes are prevalent in North America. The critical need for improved diagnostics and therapeutics for various diseases is fueling demand for proteome research and applications in drug development and personalized medicine.

Furthermore, many of the world's top biopharmaceutical companies are based in North America. These firms are actively engaged in proteomics research for medication discovery and development, contributing significantly to the region's dominant position in the worldwide Proteomics Market.

Europe:

Europe benefits from strong cross-national and institutional collaboration, which is encouraged by EU funding projects such as Horizon Europe. These collaborations and funding opportunities promote widespread proteome research, hence stimulating innovation and growth in the European Proteomics Market.

European healthcare systems are progressively implementing precision medicine approaches that rely on proteomics for biomarker identification and illness understanding. This shift towards personalized therapies is driving demand for proteomic technology and services.

Europe's strong healthcare infrastructure, which includes well-equipped laboratories and research facilities, serves as a solid platform for proteomics research and clinical applications. This infrastructure enables the development and implementation of proteomic technologies across the continent.

Furthermore, Europe bears a high load of chronic diseases, necessitating improved diagnostic and therapeutic approaches. Proteomics is critical in tackling this challenge, resulting in increased investment and interest in the discipline throughout the region.

Asia Pacific:

Asia Pacific is estimated to exhibit the highest growth during the forecast period. The region is undergoing significant economic growth, resulting in greater investment in healthcare infrastructure and research. This investment is accelerating the implementation of new technologies, such as proteomics, to improve healthcare outcomes.

Asia Pacific countries, particularly China and India, are experiencing considerable growth in their pharmaceutical and biotechnology sectors. This growth includes expanded R&D activity in proteomics for drug discovery and development, which will boost the region's Proteomics Market.

The region is experiencing an increase in chronic diseases such as cancer, cardiovascular disease, and diabetes. This has increased demand for proteome research to generate better diagnostic tools and therapeutics, driving market growth.

Furthermore, governments in the Asia Pacific are enacting legislation and providing financial assistance to encourage innovation in biotechnology and life sciences, including proteomics. Such activities are critical for developing research capacity and attracting investment, hence allowing the Proteomics Market's rapid expansion.

Global Proteomics Market: Segmentation Analysis

The Global Proteomics Market is segmented on the basis of Instrument Technologies, Reagent, Software & Service, Application, End-User, And Geography.

Proteomics Market, By Instrumentation Technologies

• Spectroscopy
• Chromatography
• Electrophoresis
• Protein Microarrays
• X-ray Crystallography
• Surface Plasmon Resonance
• Protein Fractionation
• Others

Based on Instrumentation Technologies, the market is segmented into Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-ray Crystallography, Surface Plasmon Resonance, Protein Fractionation, and Others. The spectroscopy segment is estimated to exhibit the highest growth within the Proteomics Market due to spectroscopy, particularly mass spectrometry (MS), which is critical for protein identification, quantification, and analysis. Mass spectrometry, a fundamental technique in the spectroscopy category, offers unrivaled sensitivity, precision, and depth of analysis for examining complex proteomes, making it essential for proteomics research. Its capacity to analyze a wide range of biomolecules, from small peptides to big proteins and complexes, combined with advances in MS technology, such as enhanced speed, resolution, and throughput, solidifies its position as a cornerstone technique in proteomics.

Proteomics Market, By Reagent

• Immunoassay Reagents
• Spectroscopy Reagents
• Chromatography Reagents
• Electrophoresis Reagents
• Protein Microarrays Reagents
• X-ray Crystallography Reagents
• Protein Fractionation Reagents
• Others

Based on Reagent, the market is segmented into Immunoassay, Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-ray Crystallography, Protein Fractionation Reagents, and Others. The immunoassay reagent segment is estimated to dominate the Proteomics Market due to the extensive use of immunoassays for protein identification and quantification in a variety of applications, ranging from basic research to clinical diagnosis. Immunoassay reagents are essential for many proteomic research because of their specificity, sensitivity, and adaptability in detecting and quantifying proteins and their changes. They are used in a variety of platforms, including ELISA, western blotting, and multiplex assays, to help analyze protein expression, function, and relationships.

Proteomics Market, By Software & Service

• Core Proteomics Services
• Bioinformatics Software & Services

Based on Software & Services, the market is segmented into Core Proteomics Services and Bioinformatics Software & Services. The bioinformatics software & service segment is estimated to dominate the global market due to bioinformatics' crucial role in managing, analyzing, and interpreting the massive volumes of data produced by proteomic investigations. As proteomics technology, particularly mass spectrometry, advances, the number and complexity of data grow tremendously. Bioinformatics software and services are critical tools for data analysis, visualization, and integration, allowing researchers to decode complex biological data and identify new proteins, biomarkers, and therapeutic targets.

Proteomics Market, By Application

• Clinical Diagnostics
• Drug Discovery & Development
• Others

Based on Application, the market is segmented into Clinical Diagnostics, Drug Discovery & Development, and Others. The drug discovery & development application is estimated to hold the majority share in the forecast period of the Proteomics Market due to proteomics' crucial position in the pharmaceutical and biotechnology industries, where it is widely utilized to find and validate new drug targets, study pharmacological mechanisms of action, and track therapeutic responses. The capacity of proteomics to provide complete insights into the molecular underpinnings of diseases as well as the impact of medications on the proteome makes it an invaluable tool in the drug discovery process.

Proteomics Market, By End-User

• Hospitals
• Clinical Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic Research Laboratories
• Others

Based on End-User, the market is segmented into Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Academic Research Laboratories, and Others. The pharmaceutical & biotechnology companies segment is estimated to show the highest growth in the forecasted period due to these corporations' significant investments in research and development activities such as drug discovery and development, as well as the need for precision medicine. Proteomics tools, such as mass spectrometry and protein microarrays, are critical for understanding disease causes, discovering biomarkers for diagnosis and prognosis, and creating tailored treatments.

Key Players

• The "Global Proteomics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Agilent Technologies, Bruker Corporation, Danaher Corporation, Thermo Fisher Scientific, Shimadzu Corporation, Abcam, Bio-Rad Laboratories, Charles River Laboratories, Merck KGaA, Myriad Genetics, Novogen, PerkinElmer, Proteomedix, SomaLogic, TA Instruments, and Bio-Techne.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Proteomics Market Recent Developments
• In February 2024, Bruker Corporation announced the launch of its new timsTOF Pro 2 mass spectrometer, which is specifically suited for advanced proteomics research. This equipment has increased sensitivity and speed, promising more detailed insights into complicated protein samples.
• In February 2024, Agilent Technologies and Bio-Rad Laboratories announced a collaboration to create and commercialize integrated workflow solutions for proteomics research. This collaboration seeks to streamline operations and improve data quality for researchers.
• In February 2024, Thermo Fisher Scientific expanded its clinical proteomics services by introducing new tailored mass spectrometry tests for Alzheimer's disease and other neurodegenerative disorders. This development demonstrates the rising use of proteomics in clinical diagnostics.
• In February 2024, SomaLogic, a proteomics service provider known for its SomaScan platform, announced a partnership with AstraZeneca to use its technology for drug discovery and development. This partnership demonstrates the rising use of proteomics in the pharmaceutical business.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PROTEOMICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PROTEOMICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PROTEOMICS MARKET, BY REAGENT

• 5.1 Overview
• 5.2 Immunoassay Reagents
• 5.3 Spectroscopy Reagents
• 5.4 Chromatography Reagents
• 5.5 Electrophoresis Reagents
• 5.6 Protein Microarrays Reagents
• 5.7 X-ray Crystallography Reagents
• 5.8 Protein Fractionation Reagents
• 5.9 Others

6 GLOBAL PROTEOMICS MARKET, BY INSTRUMENTATION TECHNOLOGY

• 6.1 Overview
• 6.2 Spectroscopy
• 6.3 Chromatography
• 6.4 Electrophoresis
• 6.5 Protein Microarrays
• 6.6 X-ray Crystallography
• 6.7 Surface Plasmon Resonance
• 6.8 Protein Fractionation
• 6.9 Others

7 GLOBAL PROTEOMICS MARKET, BY SOFTWARE AND SERVICE

• 7.1 Overview
• 7.2 Core Proteomics Services
• 7.3 Bioinformatics Software & Services

8 GLOBAL PROTEOMICS MARKET, BY APPLICATION

• 8.1 Overview
• 8.2 Clinical Diagnostics
• 8.3 Drug Discovery & Development
• 8.4 Others

9 GLOBAL PROTEOMICS MARKET, BY END-USER

• 9.1 Overview
• 9.2 Hospitals
• 9.3 Clinical Laboratories
• 9.4 Pharmaceutical & Biotechnology Companies
• 9.5 Academic Research Laboratories
• 9.6 Others

10 GLOBAL PROTEOMICS MARKET, BY GEOGRAPHY

• 10.1 Overview
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 U.K.
  • 10.3.3 France
  • 10.3.4 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Rest of Asia Pacific
• 10.5 Rest of the World
  • 10.5.1 Latin America
  • 10.5.2 Middle East and Africa

11 GLOBAL PROTEOMICS MARKET COMPETITIVE LANDSCAPE

• 11.1 Overview
• 11.2 Company Market Ranking
• 11.3 Key Development Strategies

12 COMPANY PROFILES

• 12.1 Agilent Technologies
  • 12.1.1 Overview
  • 12.1.2 Financial Performance
  • 12.1.3 Product Outlook
  • 12.1.4 Key Developments
• 12.2 Bruker Corporation
  • 12.2.1 Overview
  • 12.2.2 Financial Performance
  • 12.2.3 Product Outlook
  • 12.2.4 Key Developments
• 12.3 Danaher Corporation
  • 12.3.1 Overview
  • 12.3.2 Financial Performance
  • 12.3.3 Product Outlook
  • 12.3.4 Key Developments
• 12.4 Thermo Fisher Scientific
  • 12.4.1 Overview
  • 12.4.2 Financial Performance
  • 12.4.3 Product Outlook
  • 12.4.4 Key Developments
• 12.5 Bio-Rad Laboratories
  • 12.5.1 Overview
  • 12.5.2 Financial Performance
  • 12.5.3 Product Outlook
  • 12.5.4 Key Developments
• 12.6 Merck KGaA
  • 12.6.1 Overview
  • 12.6.2 Financial Performance
  • 12.6.3 Product Outlook
  • 12.6.4 Key Developments
• 12.7 SomaLogic
  • 12.7.1 Overview
  • 12.7.2 Financial Performance
  • 12.7.3 Product Outlook
  • 12.7.4 Key Developments
• 12.8 Novogen
  • 12.8.1 Overview
  • 12.8.2 Financial Performance
  • 12.8.3 Product Outlook
  • 12.8.4 Key Developments
• 12.9 Myriad Genetics
  • 12.9.1 Overview
  • 12.9.2 Financial Performance
  • 12.9.3 Product Outlook
  • 12.9.4 Key Developments
• 12.10 Abcam
  • 12.10.1 Overview
  • 12.10.2 Financial Performance
  • 12.10.3 Product Outlook
  • 12.10.4 Key Developments

13 Appendix

• 13.1 Related Research